Stock Market

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

By Bullbit Editorial · March 27, 2026

WhatEli Lilly's obesity drug, Mounjaro, is struggling to gain traction in the US market.
WhyNovo Nordisk's Wegovy has a stronger market presence and higher sales.
SignalWegovy's success may indicate a shift in the market towards Novo Nordisk's products.
TargetInvestors may want to target Novo Nordisk's stock as a more promising option.
RiskEli Lilly's stock may still hold value due to its diversified portfolio.